Context Therapeutics (CNTX) Price & Analysis

Compare

133 Followers

CNTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.49 - $2.75

Previous CloseN/A

Volume293.07K

Average Volume (3M)169.36K

Market Cap

$60.75M

Enterprise Value-$20.98M

Total Cash (Recent Filing)$89.35M

Total Debt (Recent Filing)$193.71K

Price to Earnings (P/E)―

Beta1.26

Next Earnings

Nov 05, 2025

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding89,704,190

10 Day Avg. Volume123,925

30 Day Avg. Volume169,361

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.35

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit8.17K

Enterprise Value/Ebitda0.66

Forecast

1Y Price Target

$4.25

Price Target Upside525.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical TrialsContext Therapeutics is making progress on its two T cell engaging bispecific antibodies for solid tumors, CTIM-76 and CT-95, which are currently in Phase 1 dose-escalation trials.

Financial StabilityContext remains well-capitalized with $94.4M in cash, providing financial stability and runway into 2027.

Regulatory EnvironmentThe company's TCE programs are unlikely to face increased regulatory risk due to recent changes at the FDA, which is reassuring for investors.

Bears Say

Market ConditionsCNTX shares have been pressured driven mainly by continued, challenging biotech markets and lack of catalysts as management has focused on building its portfolio.

Market PerformanceContext shares have decreased over 11%, highlighting concerns about the company's stock performance compared to market indices.

Context Therapeutics News

Context Therapeutics price target lowered to $4 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Context Therapeutics (CNTX) to $4 from $5 and keeps a...

7d ago

CNTX

Context Therapeutics reports Q2 EPS (9c), consensus (5c)

“We remain focused on progressing our clinical pipeline – CTIM-76, a selective Claudin 6 x CD3 bispecific antibody,...

7d ago

CNTX

Context Therapeutics price target lowered to $4 from $4.50 at Piper Sandler

Piper Sandler lowered the firm’s price target on Context Therapeutics (CNTX) to $4 from $4.50 and keeps an...

2M ago

CNTX

Context Therapeutics Approves Reverse Stock Split Amendment

Context Therapeutics ( ($CNTX) ) has shared an update. On June 12, 2025, Context Therapeutics Inc. held its...

2M ago

CNTX

Context Therapeutics Highlights T Cell Engager Advancements

An announcement from Context Therapeutics ( ($CNTX) ) is now available. On June 2, 2025, Context Therapeutics updated...

2M ago

CNTX

Context Therapeutics appoints Chagin as Chief Medical Officer

Context Therapeutics (CNTX) announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer, CMO, effective June...

3M ago

CNTX

Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed

Context Therapeutics (CNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

3M ago

CNTX

Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation

William Blair analyst Matt Phipps has reiterated their bullish stance on CNTX stock, giving a Buy rating on...

3M ago

CNTX

Context Therapeutics CMO Claudio Dansky Ullmann to depart

Context Therapeutics (CNTX) announced Karen Smith as interim chief medical officer. Smith replaces Claudio Dansky Ullmann, who will...

3M ago

CNTX

Innovative Bispecific Antibody CT-95 Drives Buy Rating for Context Therapeutics

Maxim Group analyst Jason McCarthy has reiterated their bullish stance on CNTX stock, giving a Buy rating on...

3M ago

CNTX

Context Therapeutics presents preclinical data on CT-95

Context Therapeutics (CNTX) announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a mesothelin x CD3...

4M ago

CNTX

Context Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Context Therapeutics (CNTX) with an Outperform rating. The biopharmaceutical industry is entering a...

4M ago

CNTX

Promising Outlook for Context Therapeutics: Buy Rating Backed by Innovative T-Cell Engagers and Strategic Pipeline Expansion

Context Therapeutics (CNTX) has received a new Buy rating, initiated by William Blair analyst, Matt Phipps. Matt Phipps...

4M ago

CNTX

Context Therapeutics Begins Phase 1 Trial for CT-95

Context Therapeutics ( ($CNTX) ) has issued an announcement. On April 9, 2025, Context Therapeutics announced the dosing...

4M ago

CNTX

CNTX FAQ

What was Context Therapeutics’s price range in the past 12 months?

Context Therapeutics lowest stock price was $0.49 and its highest was $2.75 in the past 12 months.

What is Context Therapeutics’s market cap?

Context Therapeutics’s market cap is $60.75M.

When is Context Therapeutics’s upcoming earnings report date?

Context Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 83 days.

How were Context Therapeutics’s earnings last quarter?

Context Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.062 by -$0.028.

Is Context Therapeutics overvalued?

According to Wall Street analysts Context Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Context Therapeutics pay dividends?

Context Therapeutics does not currently pay dividends.

What is Context Therapeutics’s EPS estimate?

Context Therapeutics’s EPS estimate is -0.08.

How many shares outstanding does Context Therapeutics have?

Context Therapeutics has 89,704,190 shares outstanding.

What happened to Context Therapeutics’s price movement after its last earnings report?

Context Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.062. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Context Therapeutics?

Currently, no hedge funds are holding shares in CNTX

Context Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.25%

Trailing 12-Months

Asset Growth

-15.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Context Therapeutics

Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hormone-driven cancers. The company operates in the biotechnology and healthcare sectors, with a core emphasis on advancing therapies for breast, ovarian, and endometrial cancers. Context Therapeutics is dedicated to improving patient outcomes by targeting hormone receptors and pathways that are pivotal in cancer progression.

Context Therapeutics (CNTX) Earnings & Revenues

Historic Earnings Reports

CNTX Stock 12 Month Forecast

Average Price Target

$4.25

▲(525.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,1.04,1.37,1.7,2.0300000000000002,2.3600000000000003,2.69,3.02,3.35,3.68,4.01,4.34,4.67,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.9823076923076923,1.2546153846153847,1.5269230769230768,1.7992307692307692,2.0715384615384616,2.3438461538461537,2.6161538461538463,2.8884615384615384,3.1607692307692306,3.433076923076923,3.7053846153846153,3.9776923076923074,{"y":4.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.71,0.963076923076923,1.2161538461538461,1.4692307692307693,1.7223076923076923,1.9753846153846153,2.2284615384615387,2.4815384615384617,2.7346153846153847,2.9876923076923076,3.2407692307692306,3.493846153846154,3.746923076923077,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.37,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >